ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a comprehensive clinicopathologic and molecular analysis in Chinese patients.
Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HER2-Low Breast Cancer: A Review of Epidemiology, Diagnostic Challenges, Targeted Therapies, and Clinical Outcomes.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) has become the most prevalent malignancy worldwide in recent years. Human epidermal growth factor receptor 2 (HER2) low-expressing tumors account for approximately 60% of BCs in clinical practice, and HER2 low-expression is defined as immunohistochemistry (IHC) 1+ or 2+, along with negative fluorescence in situ hybridization (FISH). Although the efficacy of antibody-drug combinations (ADCs) for the treatment of metastatic HER2 low-expressing BC has been demonstrated, there is still a lack of data on the clinicopathologic characteristics, risk of recurrence, and adjuvant treatment outcomes of early-stage HER2-overexpressing BC compared with non-HER2-overexpressing BC. The objective of this study is to explore whether the clinically validated RecurIndex assay could provide additional prognostic stratification between HER2-low and HER2-zero early-stage BCs in a real-world, single-center cohort. Methods: A retrospective analysis of data from 120 patients diagnosed with pT1-2N1M0 BC who had undergone RecurIndex testing. In order to enhance our comprehension of HER2-negative and HER2-positive tumors, we examined the clinicopathological characteristics, survival outcomes, and the RecurIndex risk model index for BCs categorized by HER2 status. Results: In our study, there were significantly fewer hormone receptor-positive (HR Conclusions: Our results demonstrated that HER2-zero group have a higher recurrence risk and poor prognosis than HER2-low group. HER2-low HR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.